Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecobalamin and Ceftriaxone for Sepsis-Induced Liver Injury
NCT06220929Phase 4Not yet recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of mecobalamin and ceftriaxone in sepsis and Liver injury (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoints: Serum Total Bilirubin Concentration and Serum Total Bile Acid Concentration. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
mecobalaminceftriaxone
03
Conditions
sepsisLiver injury
Beyond the preview
Go deeper on NCT06220929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06220929.